Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
The Polyclinic
2
mi
from 98109
Seattle, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
The Polyclinic
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Cancer Care Northwest - Spokane South
229
mi
from 98109
Spokane, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Cancer Care Northwest - Spokane South
229
mi
from 98109
Spokane, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Wenatchee Valley Hospital and Clinics
95
mi
from 98109
Wenatchee, WA
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Wenatchee Valley Hospital and Clinics
95
mi
from 98109
Wenatchee, WA
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
West Virginia University Charleston
2128
mi
from 98109
Charleston, WV
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
West Virginia University Charleston
2128
mi
from 98109
Charleston, WV
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Chippewa Center
1479
mi
from 98109
Chippewa Falls, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Chippewa Center
1479
mi
from 98109
Chippewa Falls, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Cancer Center at Sacred Heart
1477
mi
from 98109
Eau Claire, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Cancer Center at Sacred Heart
1477
mi
from 98109
Eau Claire, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Sacred Heart Hospital
1476
mi
from 98109
Eau Claire, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Sacred Heart Hospital
1476
mi
from 98109
Eau Claire, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic
1542
mi
from 98109
Marshfield, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic
1542
mi
from 98109
Marshfield, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Saint Joseph's Hospital
1541
mi
from 98109
Marshfield, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Saint Joseph's Hospital
1541
mi
from 98109
Marshfield, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Minocqua Center
1534
mi
from 98109
Minocqua, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Minocqua Center
1534
mi
from 98109
Minocqua, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic at James Beck Cancer Center
1557
mi
from 98109
Rhinelander, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic at James Beck Cancer Center
1557
mi
from 98109
Rhinelander, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic Rice Lake Center
1451
mi
from 98109
Rice Lake, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic Rice Lake Center
1451
mi
from 98109
Rice Lake, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Saint Michael's Hospital
1573
mi
from 98109
Stevens Point, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Saint Michael's Hospital
1573
mi
from 98109
Stevens Point, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Wausau Center
1558
mi
from 98109
Wausau, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Wausau Center
1558
mi
from 98109
Wausau, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Diagnostic and Treatment Center
1564
mi
from 98109
Weston, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Diagnostic and Treatment Center
1564
mi
from 98109
Weston, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Weston Center
1564
mi
from 98109
Weston, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Weston Center
1564
mi
from 98109
Weston, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Marshfield Clinic - Wisconsin Rapids Center
1566
mi
from 98109
Wisconsin Rapids, WI
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Marshfield Clinic - Wisconsin Rapids Center
1566
mi
from 98109
Wisconsin Rapids, WI
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Welch Cancer Center
759
mi
from 98109
Sheridan, WY
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Welch Cancer Center
759
mi
from 98109
Sheridan, WY
Click here to add this to my saved trials
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated:  8/28/2015
Tom Baker Cancer Centre
440
mi
from 98109
Calgary,
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Status: Enrolling
Updated: 8/28/2015
Tom Baker Cancer Centre
440
mi
from 98109
Calgary,
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
City of Hope Cancer Center
959
mi
from 98109
Duarte, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
City of Hope Cancer Center
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
962
mi
from 98109
Los Angeles, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Stanford University
705
mi
from 98109
Stanford, CA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Stanford University
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Robert H. Lurie Comprehensive Cancer Center, Center of Northwestern University
1733
mi
from 98109
Chicago, IL
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Robert H. Lurie Comprehensive Cancer Center, Center of Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Lahey Clinic
2474
mi
from 98109
Burlington, MA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Lahey Clinic
2474
mi
from 98109
Burlington, MA
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Wayne State University/Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Wayne State University/Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Vanderbilt-Ingram Cancer Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
University of Utah, Huntsman Cancer Institute
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated:  8/28/2015
Univ of Washington
2
mi
from 98109
Seattle, WA
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma
Status: Enrolling
Updated: 8/28/2015
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
1029
mi
from 98109
Aurora, CO
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
2432
mi
from 98109
New Haven, CT
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
Boehringer Ingelheim Investigational Site
2401
mi
from 98109
New York, NY
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
Boehringer Ingelheim Investigational Site
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
1971
mi
from 98109
Nashville, TN
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1200.71.2002 Boehringer Ingelheim Investigational Site
4860
mi
from 98109
Amsterdam,
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1200.71.2002 Boehringer Ingelheim Investigational Site
4860
mi
from 98109
Amsterdam,
Click here to add this to my saved trials
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
Status: Enrolling
Updated:  8/31/2015
Local Institution
1932
mi
from 98109
Detroit, MI
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
Status: Enrolling
Updated: 8/31/2015
Local Institution
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Status: Enrolling
Updated:  8/31/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Status: Enrolling
Updated: 8/31/2015
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of California, San Diego Medical Center
1049
mi
from 98109
La Jolla, CA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of California, San Diego Medical Center
1049
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Palm Beach Institute of Hematology and Oncology
2702
mi
from 98109
Boynton Beach, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Palm Beach Institute of Hematology and Oncology
2702
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of Miami
2730
mi
from 98109
Miami, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of Miami
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Medical Oncology LLC
2035
mi
from 98109
Baton Rouge, LA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Medical Oncology LLC
2035
mi
from 98109
Baton Rouge, LA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Annapolis Oncology Center
2343
mi
from 98109
Annapolis, MD
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Annapolis Oncology Center
2343
mi
from 98109
Annapolis, MD
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Dana-Farber Cancer Center
2485
mi
from 98109
Boston, MA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Dana-Farber Cancer Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials